Dewpoint_Logo.jpg
Dewpoint Therapeutics Announces Nomination of First C-Mod Development Candidate DPTX3186 for Treatment of Wnt-Driven Cancers
October 28, 2024 08:00 ET | Dewpoint Therapeutics
Orally administered small molecule condensate modulators (c-mods) are a novel class of therapeutic agents designed to target condensates to modify diseaseDPTX3186 is Dewpoint’s first development...
Dewpoint_Logo.jpg
Bayer and Dewpoint Therapeutics sign Licensing Agreement for Heart Disease Program
October 24, 2024 08:00 ET | Dewpoint Therapeutics
Bayer obtains global license to develop and commercialize disease-modifying treatment specifically for dilated cardiomyopathy (DCM) patients characterized by specific mutationsPost-licensing,...
Dewpoint_Logo.jpg
Dewpoint Therapeutics Awarded Target ALS Grant for the Second Time for Development of c-mods for Amyotrophic Lateral Sclerosis (ALS)
August 26, 2024 09:00 ET | Dewpoint Therapeutics
Grant to support the in vivo development of first-in-class condensate-modifying drugs (c-mods) targeting the TDP-43 condensatopathy in ALS BOSTON, Aug. 26, 2024 (GLOBE NEWSWIRE) -- Dewpoint...
Dewpoint_Logo.jpg
Dewpoint Therapeutics Awarded Target ALS Grant for Development of C-mods for ALS
January 16, 2024 09:00 ET | Dewpoint Therapeutics
The in-kind Target ALS Foundational grant will support the development of first-in-class condensate-modifying drugs (c-mods) targeting the TDP-43 condensatopathy in ALS animal model BOSTON, Jan. ...
Dewpoint_Logo.jpg
Dewpoint Therapeutics Filed Multiple Patent Applications with the US Patent Office on Novel Composition of Matter for the Treatment of ALS
January 07, 2024 15:00 ET | Dewpoint Therapeutics
Patent applications reinforce Dewpoint’s leadership in the discovery of condensate-modifying drugs (c-mods) to treat diseases of high unmet needNew first-in-class composition of matter targeting...
Dewpoint_Logo.jpg
Dewpoint Therapeutics Enters Strategic Partnership with Evotec to Accelerate Oncology Pipeline
November 07, 2023 01:30 ET | Dewpoint Therapeutics
PARTNERSHIP TO ACCELERATE DEWPOINT’S LEADING ONCOLOGY PIPELINE PROGRAMS TO INVESTIGATIONAL NEW DRUG APPLICATIONS COLLABORATION LEVERAGES EVOTEC’S FULLY INTEGRATED, CLINICAL-ENABLING INDIGO CAPABILITY...